Inventiva (NASDAQ:IVA) Shares Gap Down – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped down prior to trading on Monday . The stock had previously closed at $4.30, but opened at $4.17. Inventiva shares last traded at $4.18, with a volume of 13,681 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Piper Sandler initiated coverage on Inventiva in a research report on Wednesday, August 27th. They set an “overweight” rating and a $26.00 price target for the company. HC Wainwright upped their target price on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price target on shares of Inventiva in a research report on Tuesday, September 30th. Finally, Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a report on Saturday, October 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Inventiva currently has an average rating of “Moderate Buy” and an average target price of $17.33.

Inventiva Price Performance

The stock’s fifty day moving average is $4.99 and its 200-day moving average is $4.22.

Institutional Trading of Inventiva

Several institutional investors have recently made changes to their positions in IVA. Creative Planning acquired a new position in Inventiva in the second quarter valued at approximately $32,000. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Inventiva by 54.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after purchasing an additional 5,843 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of Inventiva during the 3rd quarter worth $116,000. Finally, Millennium Management LLC purchased a new position in shares of Inventiva during the 3rd quarter worth $649,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.